Equities

BioSig Technologies Inc

BSGM:NAQ

BioSig Technologies Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.40
  • Today's Change-0.35 / -20.00%
  • Shares traded137.08k
  • 1 Year change-63.98%
  • Beta0.4954
Data delayed at least 15 minutes, as of Nov 14 2024 17:06 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects BioSig Technologies Inc share price to rise to 2.50 in the next year from the last price of 1.75.
High42.9%2.50
Med42.9%2.50
Low42.9%2.50

Earnings history & estimates in USD

On Aug 14, 2024, BioSig Technologies Inc reported 2nd quarter 2024 losses of -0.300 per share.
The next earnings announcement is expected on Nov 14, 2024.
Average growth rate+24.65%
BioSig Technologies Inc reported annual 2023 losses of -3.95 per share on Apr 16, 2024.
Average growth rate+26.69%
More ▼

Revenue history & estimates in USD

BioSig Technologies, Inc. had 2nd quarter 2024 revenues of 13.00k. The one analyst following the company did not expect it to generate revenues. This was 160.00% above the prior year's 2nd quarter results.
Average growth rate+369.84%
BioSig Technologies, Inc. had revenues for the full year 2023 of 18.00k. This was 92.91% below the prior year's results.
Average growth rate-45.11%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.